Entera Bio Ltd
ENTX1.040USD
-0.130-11.11%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
47.49MMarket Cap
LossP/E TTM
More Details of Entera Bio Ltd Company
Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
Entera Bio Ltd Info
Ticker SymbolENTX
Company nameEntera Bio Ltd
IPO dateJun 28, 2018
CEOToledano (Miranda Jayne)
Number of employees18
Security typeOrdinary Share
Fiscal year-endJun 28
AddressHadassah / Jerusalem Bio
CityJERUSALEM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code9112002
Phone97225327151
Websitehttps://enterabio.com/
Ticker SymbolENTX
IPO dateJun 28, 2018
CEOToledano (Miranda Jayne)
Company Executives of Entera Bio Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Gerald M. (Jerry) Lieberman
Mr. Gerald M. (Jerry) Lieberman
Independent Chairman of the Board
Independent Chairman of the Board
363.25K
+38294.00%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Chief Executive Officer, Director
Chief Executive Officer, Director
302.45K
+11000.00%
Mr. Sean Ellis
Mr. Sean Ellis
Independent Director
Independent Director
160.10K
+25371.00%
Ms. Haya Taitel
Ms. Haya Taitel
Independent Director
Independent Director
90.98K
+26329.00%
Mr. Yonatan Malca
Mr. Yonatan Malca
Independent Director
Independent Director
77.42K
+30157.00%
Mr. Gerald M. (Jerry) Ostrov
Mr. Gerald M. (Jerry) Ostrov
Independent Director
Independent Director
75.66K
+28721.00%
Dr. Hillel Galitzer
Dr. Hillel Galitzer
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Roger J. Garceau, M.D.
Dr. Roger J. Garceau, M.D.
Director
Director
--
--
Dr. Arthur C. Santora
Dr. Arthur C. Santora
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Dana Yaacov-Garbeli
Ms. Dana Yaacov-Garbeli
Chief Financial Officer
Chief Financial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Gerald M. (Jerry) Lieberman
Mr. Gerald M. (Jerry) Lieberman
Independent Chairman of the Board
Independent Chairman of the Board
363.25K
+38294.00%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Chief Executive Officer, Director
Chief Executive Officer, Director
302.45K
+11000.00%
Mr. Sean Ellis
Mr. Sean Ellis
Independent Director
Independent Director
160.10K
+25371.00%
Ms. Haya Taitel
Ms. Haya Taitel
Independent Director
Independent Director
90.98K
+26329.00%
Mr. Yonatan Malca
Mr. Yonatan Malca
Independent Director
Independent Director
77.42K
+30157.00%
Mr. Gerald M. (Jerry) Ostrov
Mr. Gerald M. (Jerry) Ostrov
Independent Director
Independent Director
75.66K
+28721.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Feb 6
Updated: Fri, Feb 6
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Knoll Capital Management, LLC
12.83%
OPKO Health Inc
8.43%
D.N.A Biomedical Solutions, Ltd.
8.14%
Centillion Fund Inc
5.23%
Point72 Asset Management, L.P.
2.57%
Other
62.81%
Shareholders
Shareholders
Proportion
Knoll Capital Management, LLC
12.83%
OPKO Health Inc
8.43%
D.N.A Biomedical Solutions, Ltd.
8.14%
Centillion Fund Inc
5.23%
Point72 Asset Management, L.P.
2.57%
Other
62.81%
Shareholder Types
Shareholders
Proportion
Corporation
21.80%
Hedge Fund
17.54%
Individual Investor
2.76%
Investment Advisor/Hedge Fund
1.41%
Investment Advisor
0.64%
Research Firm
0.11%
Venture Capital
0.02%
Other
55.72%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
31
10.02M
22.66%
--
2025Q3
32
10.02M
22.66%
-49.40K
2025Q2
33
10.07M
22.72%
-152.10K
2025Q1
34
10.22M
23.69%
-537.14K
2024Q4
32
7.49M
20.14%
+518.60K
2024Q3
30
5.32M
15.79%
+29.98K
2024Q2
29
5.29M
11.96%
+1.38M
2024Q1
26
4.27M
12.41%
-130.45K
2023Q4
26
4.07M
8.01%
+1.48M
2023Q3
27
2.59M
10.16%
+9.25K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Knoll Capital Management, LLC
5.88M
12.83%
--
--
Sep 30, 2025
OPKO Health Inc
3.87M
8.43%
+180.00K
+4.88%
May 08, 2025
D.N.A Biomedical Solutions, Ltd.
3.73M
8.14%
--
--
May 08, 2025
Centillion Fund Inc
2.40M
5.23%
--
--
May 08, 2025
Point72 Asset Management, L.P.
1.18M
2.57%
-1.52M
-56.31%
Sep 30, 2025
Marshall Wace LLP
627.33K
1.37%
+627.33K
--
Sep 30, 2025
Schonfeld Strategic Advisors LLC
566.96K
1.24%
-37.57K
-6.21%
Sep 30, 2025
Lieberman (Gerald M)
324.96K
0.71%
--
--
May 08, 2025
Toledano (Miranda Jayne)
302.45K
0.66%
+11.00K
+3.77%
Dec 29, 2025
Parkman Healthcare Partners LLC
280.82K
0.61%
-75.00K
-21.08%
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
